Ken Garber. Show Affiliations »
Abstract
Entities: Chemical
Mesh: See more » Antibodies, Monoclonal/pharmacologyAntibodies, Monoclonal/therapeutic useAntigens, CD/drug effectsAntigens, CD/immunologyAntineoplastic Agents/adverse effectsAntineoplastic Agents/pharmacologyAntineoplastic Agents/therapeutic useAntineoplastic Combined Chemotherapy Protocols/pharmacologyApoptosis Regulatory Proteins/drug effectsApoptosis Regulatory Proteins/immunologyCD40 Antigens/drug effectsCD40 Antigens/immunologyClinical Trials, Phase III as TopicDrug ApprovalGlucocorticoid-Induced TNFR-Related Protein/drug effectsGlucocorticoid-Induced TNFR-Related Protein/immunologyHumansImmunological Synapses/drug effectsImmunotherapy/methodsIpilimumabLymphocyte Activation/drug effectsMelanoma/drug therapyMelanoma/immunologyNeoplasms/drug therapyNeoplasms/immunologyNivolumabOX40 Ligand/drug effectsOX40 Ligand/immunologyProgrammed Cell Death 1 ReceptorSkin Neoplasms/drug therapySkin Neoplasms/immunologyT-Lymphocytes/drug effectsT-Lymphocytes/immunology
Substances: See more » Antibodies, MonoclonalAntigens, CDAntineoplastic AgentsApoptosis Regulatory ProteinsCD40 AntigensGlucocorticoid-Induced TNFR-Related ProteinIpilimumabOX40 LigandPDCD1 protein, humanProgrammed Cell Death 1 ReceptorTNFRSF18 protein, humanTNFSF4 protein, humanNivolumab
Year: 2011 PMID: 21737695 DOI: 10.1093/jnci/djr281
Source DB: PubMed Journal: J Natl Cancer Inst ISSN: 0027-8874 Impact factor: 13.506